{
    "nct_id": "NCT04176172",
    "official_title": "Testing Novel Pharmacogenetic and Adherence Optimization Treatments to Improve the Effectiveness of Smoking Cessation Treatments for Smokers with HIV",
    "inclusion_criteria": "* >18 years, smoke daily for the past 30 days\n* Confirmed HIV+ (exhibit viral load of <1000 copies/mL)\n* Residing in the geographic area close to one of the sites for at least 7 months\n* Able to use varenicline/TN patch safely\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Current untreated and unstable diagnosis of substance abuse/dependence\n* Current diagnosis of unstable and untreated major depression, psychosis or bipolar disorder\n* Suicide risk as measured by the C-SSRS\n* Current use or discontinuation within last 14 days of quit smoking medications\n* Cancer, heart disease, stroke or MI within the past 6 months requires study physician approval\n* Uncontrolled hypertension\n* History of epilepsy or seizure disorder requires study physician approval\n* Women who are pregnant, planning a pregnancy, or lactating\n* Use of e-cigarettes, chewing tobacco, snuff or snus\n* Generalized eczema or psoriasis\n* A reaction or sensitivity to a nicotine patch or any other transdermal medication requires study physician approval\n* Currently participating in a smoking cessation program",
    "miscellaneous_criteria": "Key"
}